Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series E results in $55mm for Versartis

Executive Summary

Just four months after closing a $20mm Series D financing, Versartis Inc. (working on growth hormone deficiency--GHD--treatments) raised $55mm in Series E funds from five undisclosed new backers and returning shareholders Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners, and Advent Venture Partners. The money will move its pediatric GHD candidate VRS317 into Phase III.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies